The temporary use of the bioenterics intragastric balloon in morbid obesity is increasing worldwide. Generally, this is an effective procedure that helps bring about satisfactory weight loss and improvement in comorbidities after 6 months. However, in some cases, it causes complications such as acute abdomen due to gastric perforation and even death. We describe the case of a type II obese female (weight, 88 kg; body mass index, 35.2 kg/m(2)) who underwent emergency surgery for gastric necrosis caused by bioenterics intragastric balloon; the patient required total gastrectomy and intensive care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11695-009-9855-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Outcomes in Patients Undergoing Sequential Intragastric Balloon (IGB) Treatment for Super Obesity: A Single Centre Retrospective Analysis.
J Metab Bariatr Surg
December 2024
Department of General Surgery, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, Yorkshire, United Kingdom.
Purpose: We aimed to assess outcomes in patients undergoing sequential intragastric balloon (IGB) treatment for obesity.
Materials And Methods: Consecutive patients who underwent treatment between May 2014 and February 2023 were identified. We recorded outcomes including: weight at 3-monthly intervals, progression to definitive bariatric procedure and morbidity.
The Effect of Tacrine on Functional Response of the Lower Oesophageal Sphincter Assessed by Endoscopic Luminal Impedance Planimetry in Experimental Pigs.
Pharmaceuticals (Basel)
November 2024
Biomedical Research Centre, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic.
Tacrine is a centrally active non-competitive reversible acetylcholinesterase inhibitor. It also exerts antagonising activity against -methyl-D-aspartate receptors. Tacrine was approved for the treatment of Alzheimer's disease in 1993, but was withdrawn from clinical use in 2013 because of its hepatotoxicity and gastrointestinal side effects.
View Article and Find Full Text PDFIntragastric balloon adverse events: a comprehensive MAUDE database review.
Proc (Bayl Univ Med Cent)
October 2024
Department of Gastroenterology and Hepatology, The University of Florida College of Medicine - Jacksonville, Jacksonville, Florida, USA.
Background: Endoscopic bariatric interventions are viable alternatives to traditional weight loss surgeries for patients with a body mass index between 30 and 40 kg/m. While studies have explored the impact of intragastric balloons on obesity and weight reduction, comprehensive data on real-world device-related complications and failures are limited. This study aimed to investigate mechanical failures leading to patient adverse events reported to the US Food and Drug Administration.
View Article and Find Full Text PDFBurst that Bubble. Gastric Perforation from an Ingested Intragastric Balloon: A Case Report.
Clin Pract Cases Emerg Med
November 2024
Texas Tech University Health Sciences Center at El Paso, Department of Emergency Medicine, El Paso, Texas.
Introduction: More than 40% of Americans are considered obese, resulting in annual healthcare costs estimated at $173 billion., Various interventions exist to address obesity including lifestyle modification, medications, and several surgical options. A novel ingestible intragastric balloon that self-deflates and is excreted approximately four months post-ingestion is being used in other countries such as Australia, Mexico, and several European countries.
View Article and Find Full Text PDFDiet Biofunctionality in Modulating Cardiovascular Parameters in Obese Patients After Bioenteric Intragastric Balloon Bariatric Surgery.
Nutrients
November 2024
Unii Lubelskiej 1, Department of General, Minimally Invasive and Gastroenterological Surgery, Independent Public Clinical Hospital No. 1 of Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland.
Background/objectives: Adiposopathy is the cause of many secondary disorders in the function and structure of many organs and systems in the body. In the progression of obesity and the increasing dysfunction of anti-inflammatory me-diators, chronic inflammation occurs. This may be accompanied by the development of metabolic complications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!